Supriya Lifescience

Supriya Lifescience Operating Cash Flow

The Operating Cash Flow of Supriya Lifescience (SUPRIYA.NS) as of Oct 29, 2026 is 1.95 B INR. In the previous year, Operating Cash Flow was 1.73 B INR — a change of 13.13% (higher).

Operating Cash Flow

1.95 BINR

YoY

13.13%

Last updated:

Operating Cash Flow of Supriya Lifescience is 2026 1.95 B INR. Operating Cash Flow of Supriya Lifescience was 2025 1.73 B INR. It decreases by 13.13% higher compared to the previous year.

The Supriya Lifescience Operating Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Operating Cash Flow
Date
Operating Cash Flow
Jan 1, 2019
486.72 M INR
Jan 1, 2020
1.16 B INR
Jan 1, 2021
799.30 M INR
Jan 1, 2022
488.01 M INR
Jan 1, 2023
661.87 M INR
Jan 1, 2024
1.13 B INR
Jan 1, 2025
1.73 B INR
Jan 1, 2026
1.95 B INR
The Supriya Lifescience Operating Cash Flow history
YEAROperating Cash FlowYoY
1.95 BINR+13.13%
1.73 BINR+52.30%
1.13 BINR+71.19%
661.87 MINR+35.63%
488.01 MINR-38.95%
799.30 MINR-31.13%
1.16 BINR+138.46%
486.72 MINR+178.89%
174.52 MINR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Supriya Lifescience Stock analysis

What does Supriya Lifescience do? Supriya Lifescience Ltd. generates revenue through the manufacturing and export of active pharmaceutical ingredients (APIs) focused on niche therapeutic segments. The company produces approximately 38 API products, including Chlorphenamine Maleate, Pheniramine Maleate, and Cetirizine DiHCL, which address antihistamine, analgesic, vitamin, anesthetics, and anti-asthma therapies. These products are exported to around 86 countries, targeting pharmaceutical manufacturers and healthcare providers seeking specialized chemical compounds for drug formulations. The firm's manufacturing facilities in Maharashtra support the production of bulk drugs and pharmaceutical chemicals, with a strong emphasis on research and development to maintain its niche market position. The company's product portfolio includes specialized compounds such as Bisoprolol Fumarate, Nicorandil, and Mecobalamin, which cater to specific medical needs in cardiovascular and neurological treatments. By concentrating on high-demand therapeutic areas like antihistamines and anti-asthma solutions, Supriya Lifescience Ltd. serves pharmaceutical companies globally that require reliable sources of API raw materials. Its export-driven model ensures steady demand from international clients across diverse healthcare markets. Supriya Lifescience Ltd. leverages its research and development capabilities to develop and refine its API offerings, ensuring compliance with global pharmaceutical standards. The firm's focus on niche products allows it to differentiate itself in a competitive market, attracting buyers who prioritize specialized chemical solutions over generic alternatives. With a manufacturing base in Maharashtra, the company efficiently scales production to meet the growing global demand for its targeted therapeutic APIs. Supriya Lifescience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Supriya Lifescience stock

Operating Cash Flow of Supriya Lifescience is 1.95 B INR in 2026.

Operating Cash Flow of Supriya Lifescience changed from 1.73 B INR to 1.95 B INR, representing a 13.13% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Supriya Lifescience since 2006 – with annual values, charts, and detailed analysis.

Operating cash flow measures the cash generated from core business operations. It is a pure measure of a company's ability to generate cash.

Operating Cash Flow's INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Operating Cash Flow's Supriya Lifescience historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Supriya Lifescience

All Key Metrics — Supriya Lifescience